Oncotarget

Research Papers:

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells

Gabriele Stefanzl, Daniela Berger, Sabine Cerny-Reiterer, Katharina Blatt, Gregor Eisenwort, Wolfgang R. Sperr, Gregor Hoermann, Karin Lind, Alexander W. Hauswirth, Peter Bettelheim, Heinz Sill, Junia V. Melo, Ulrich Jäger and Peter Valent _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:67709-67722. https://doi.org/10.18632/oncotarget.18810

Metrics: PDF 608 views  |   HTML 984 views  |   ?  


Abstract

Gabriele Stefanzl1,2,*, Daniela Berger1,*, Sabine Cerny-Reiterer1,2, Katharina Blatt1,2, Gregor Eisenwort1,2, Wolfgang R. Sperr1,2, Gregor Hoermann2,3, Karin Lind4, Alexander W. Hauswirth1,2, Peter Bettelheim5, Heinz Sill4, Junia V. Melo6, Ulrich Jäger1,2 and Peter Valent1,2

1Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria

2The Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

3Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

4Department of Internal Medicine, Division of Hematology, Medical University of Graz, Graz, Austria

5Division of Laboratory Medicine, Elisabethinen Hospital Linz, Linz, Austria

6Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia

*These authors have contributed equally to this work

Correspondence to:

Peter Valent, email: peter.valent@meduniwien.ac.at

Keywords: ALL, targeting-concepts, BCL-2 family members, PI3-Kinase, mTOR

Received: December 21, 2016     Accepted: June 02, 2017     Published: June 28, 2017

ABSTRACT

Acute lymphoblastic leukemia (ALL) is characterized by leukemic expansion of lymphoid blasts in hematopoietic tissues. Despite improved therapy only a subset of patients can be cured. Therefore, current research is focusing on new drug-targets. Members of the BCL-2 family and components of the PI3-kinase/mTOR pathway are critically involved in the regulation of growth and survival of ALL cells. We examined the effects of the pan-BCL-2 blocker obatoclax and the PI3-kinase/mTOR-inhibitor BEZ235 on growth and survival of ALL cells. In 3H-thymidine uptake experiments, both drugs suppressed the in vitro proliferation of leukemic cells in all patients with Philadelphia chromosome-positive (Ph+) ALL and Ph ALL (obatoclax IC50: 0.01-5 μM; BEZ235, IC50: 0.01-1 μM). Both drugs were also found to produce growth-inhibitory effects in all Ph+ and all Ph cell lines tested. Moreover, obatoclax and BEZ235 induced apoptosis in ALL cells. In drug-combination experiments, obatoclax and BEZ235 exerted synergistic growth-inhibitory effects on ALL cells. Finally, we confirmed that ALL cells, including CD34+/CD38 stem cells and all cell lines express transcripts for PI3-kinase, mTOR, BCL-2, MCL-1, and BCL-xL. Taken together, this data shows that combined targeting of the PI3-kinase/mTOR-pathway and BCL-2 family-members is a potent approach to counteract growth and survival of ALL cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18810